PREDICTORS AND OUTCOMES OF BIOLOGIC/IMMUNOSUPPRESSIVE THERAPY FOR PSC-ASSOCIATED IBD
Sayed A, Silveira M, Assis D, Deng Y, Gaidos J, Proctor D, Al-Bawardy B. PREDICTORS AND OUTCOMES OF BIOLOGIC/IMMUNOSUPPRESSIVE THERAPY FOR PSC-ASSOCIATED IBD. Inflammatory Bowel Diseases 2022, 28: s76-s76. DOI: 10.1093/ibd/izac015.124.Peer-Reviewed Original ResearchPrimary sclerosing cholangitisInflammatory bowel diseasePSC-IBDSmall bowel involvementClinical remissionEndoscopic healingIMM groupAutoimmune hepatitisBowel involvementUrsodeoxycholic acidExact testBackground Inflammatory bowel diseaseEpisodes of cholangitisRate of cholangitisThird of patientsUnpaired Student's t-testFisher's exact testT-testSmall molecule therapiesStudent's t-testThiopurine monotherapyImmunosuppressive therapySclerosing cholangitisAdult patientsBiologic therapyIMPACT OF THIOPURINE DOSE IN COMBINATION THERAPY IN INFLAMMATORY BOWEL DISEASE
Nawaz A, Glick L, Li D, Gaidos J, Proctor D, Al-Bawardy B. IMPACT OF THIOPURINE DOSE IN COMBINATION THERAPY IN INFLAMMATORY BOWEL DISEASE. Inflammatory Bowel Diseases 2022, 28: s107-s108. DOI: 10.1093/ibd/izac015.174.Peer-Reviewed Original ResearchSteroid-free clinical remissionC-reactive proteinNon-therapeutic dosesInflammatory bowel diseaseNormal C-reactive proteinAnti-TNF antibodiesCombination therapyTherapeutic doseEndoscopic healingNTD groupAntibody formationUlcerative colitisClinical outcomesCrohn's diseaseNormal serum C-reactive proteinAnti-TNF combination therapyAnti-TNF drug levelsSerum C-reactive proteinEffect of thiopurinesImpact of thiopurinesAnti-TNF treatmentRetrospective cohort studyNormal TPMT activityUnpaired Student's t-testTerms of baseline